肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
这些数据表明stIL15-OPS-γδ T细胞是一种候选的同种异体细胞治疗平台，结合了直接细胞溶解和旁观者激活以促进肿瘤控制。
The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing
我们的研究表明，GADEKILL具有潜在的抗神经母细胞瘤活性，支持其治疗用途，尤其是在GD2低表达的复发/难治性R/R HR-NB中。
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1.
高危神经母细胞瘤的儿科患者常因化疗耐药、无法治愈的疾病而复发。
Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.
这些结果提示，CD3/GD2 BiTE与人Vγ9Vδ2 T细胞的联合方案未来可能成为治疗神经母细胞瘤患者的一种替代性免疫治疗策略。
MEMBER ACCOUNT
登录成功会直接打开下一页。
